The plantar fasciitis treatment market size is expected to see exponential growth in the next few years. It will grow to $3.82 billion in 2028 at a compound annual growth rate (CAGR) of 23.1%. The anticipated growth in the forecast period can be linked to regulatory changes and approvals, the adoption of patient-centric approaches, increased investment in research and clinical trials, a heightened focus on personalized medicine, and the growing aging population. Significant trends expected in the forecast period encompass the development of focused rehabilitation techniques, innovations in orthopedic devices, advancements in biomechanical studies, progress in alternative therapies, and an emphasis on patient education and self-care.
The growth of the plantar fasciitis market is expected to be driven by an increase in obesity. Obesity, characterized by abnormal or excessive fat buildup, poses a health risk, with a significantly higher such aslihood of individuals with a body mass index (BMI) of 30 or higher experiencing plantar fasciitis compared to those with a normal weight. For example, a report from Forbes in January 2023 indicated a 3% increase in the obesity rate in the United States during the COVID-19 pandemic from March 2020 to March 2021. Consequently, the upward trend in obesity is a key factor fueling the growth of the plantar fasciitis market.
The growth of the plantar fasciitis treatment market is anticipated to be propelled by the rising prevalence of diabetes. Diabetes, characterized by elevated blood sugar levels, leads to complications such as foot pain and discomfort due to inflammation of the plantar fascia. Plantar fasciitis treatment in diabetes aims to alleviate these symptoms, enhance mobility, and reduce the risk of complications. The IDF Diabetes Atlas reported in 2021 that globally, 537 million people were affected by diabetes, with an estimated 643 million individuals projected to be impacted by 2030 and a significant increase to 783 million by 2045. This surge in diabetes cases is a major driver for the plantar fasciitis treatment market.
Technological advancements are emerging as a prominent trend in the plantar fasciitis treatment market. Leading companies in the market are actively developing and implementing innovative technologies to transform the treatment landscape for plantar heel pain. In December 2022, ZetrOZ Systems introduced the Sam X1, a wireless ultrasound device with FDA certification for at-home usage, offering a regenerative treatment alternative for soft tissue injuries and plantar fasciitis. This device, proven effective in treating various injuries, widens blood vessels to enhance blood flow, promoting healing without drugs or surgery.
Major companies in the plantar fasciitis treatment market are focusing on technological initiatives such as dedicated platforms for accessing global 3D foot scan data. Aetrex, a US-based foot technology company, launched the Foot.com Data Portal in September 2022, providing footwear brands with comprehensive 3D foot scan data to enhance the development of better-fitting shoes. The portal, supported by Aetrex's foot scanners, Albert 2 Pro and Albert 3DFit, offers accurate measurements and assists brands in improving the design of anatomically correct lasts for enhanced comfort and performance.
In October 2022, Patient Square Capital's acquisition of Hanger Inc. for approximately $1.25 billion is a noteworthy development in the plantar fasciitis treatment market. This acquisition is expected to support Hanger in future growth initiatives, particularly in providing innovative and high-quality care through its medical devices, including ankle-foot orthoses (AFO) used in the treatment of plantar fasciitis.
Major companies operating in the plantar fasciitis treatment market report are Bayer AG, Superfeet Worldwide LLC, Bauerfeind AG, Ottobock SE & Co. KGaA, Shapecrunch Technology Pvt. Ltd., Sanofi SA, Eli Lilly and Company, GlaxoSmithKline plc, Pfizer Inc., Allergan plc., Bristol-Myers Squibb Company, F. Hoffmann-La Roche Ltd., Scholl’s Wellness Co., Algeo Limited, Hanger Inc., Merck & Co. Inc., Novartis AG, Johnson & Johnson Services Inc., Stryker Corporation, Zimmer Biomet Holdings Inc., Smith & Nephew plc, Arthrex Inc., DJO Global Co., Medline Industries Inc., Bird & Cronin Inc., Hoya Corp., Aetrex Worldwide Inc., Vionic Group LLC.
North America was the largest region in the plantar fasciitis treatment market in 2023. The regions covered in the plantar fasciitis treatment market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the plantar fasciitis treatment market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.
The primary categories of plantar fasciitis treatment include medication therapy, orthotics, shockwave therapy, surgery, and other interventions. Medication therapy involves treating the condition using prescription or non-prescription medicines, over-the-counter medications, and herbal remedies. Diagnosis typically relies on medical history, physical examination, X-rays, radiography, and other diagnostic methods and is administered by hospitals, clinics, and other healthcare providers.
The plantar fasciitis treatment market research report is one of a series of new reports that provides plantar fasciitis treatment market statistics, including plantar fasciitis treatment industry global market size, regional shares, competitors with a plantar fasciitis treatment market share, detailed plantar fasciitis treatment market segments, market trends and opportunities, and any further data you may need to thrive in the plantar fasciitis treatment industry. This plantar fasciitis treatment market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
This product will be delivered within 3-5 business days.
Table of Contents
Executive Summary
Plantar Fasciitis Treatment Global Market Report 2024 provides strategists, marketers and senior management with the critical information they need to assess the market.This report focuses on plantar fasciitis treatment market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.
Reasons to Purchase
- Gain a truly global perspective with the most comprehensive report available on this market covering 50+ geographies.
- Understand how the market has been affected by the COVID-19 and how it is responding as the impact of the virus abates.
- Assess the Russia-Ukraine war’s impact on agriculture, energy and mineral commodity supply and its direct and indirect impact on the market.
- Measure the impact of high global inflation on market growth.
- Create regional and country strategies on the basis of local data and analysis.
- Identify growth segments for investment.
- Outperform competitors using forecast data and the drivers and trends shaping the market.
- Understand customers based on the latest market shares.
- Benchmark performance against key competitors.
- Suitable for supporting your internal and external presentations with reliable high quality data and analysis
- All data from the report will also be delivered in an excel dashboard format.
Description
Where is the largest and fastest growing market for plantar fasciitis treatment? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? This report answers all these questions and many more.The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market’s historic and forecast market growth by geography.
Scope
Markets Covered:1) By Type: Medication Therapy; Orthotics; Shockwave Therapy; Surgery; Other Types
2) By Diagnosis: Medical History; Physical Examination; X-Rays; Radiography; Other Diagnosis
3) By End User: Hospitals; Clinics; Other End Users
Companies Mentioned: Bayer AG; Superfeet Worldwide LLC; Bauerfeind AG; Ottobock SE & Co. KGaA; Shapecrunch Technology Pvt. Ltd.
Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
Time series: Five years historic and ten years forecast.
Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
Delivery format: PDF, Word and Excel Data Dashboard.
Companies Mentioned
- Bayer AG
- Superfeet Worldwide LLC
- Bauerfeind AG
- Ottobock SE & Co. KGaA
- Shapecrunch Technology Pvt. Ltd.
- Sanofi SA
- Eli Lilly and Company
- GlaxoSmithKline plc
- Pfizer Inc.
- Allergan plc.
- Bristol-Myers Squibb Company
- F. Hoffmann-La Roche Ltd.
- Scholl’s Wellness Co.
- Algeo Limited
- Hanger Inc.
- Merck & Co. Inc.
- Novartis AG
- Johnson & Johnson Services Inc.
- Stryker Corporation
- Zimmer Biomet Holdings Inc.
- Smith & Nephew plc
- Arthrex Inc.
- DJO Global Co.
- Medline Industries Inc.
- Bird & Cronin Inc.
- Hoya Corp.
- Aetrex Worldwide Inc.
- Vionic Group LLC
Methodology
LOADING...